PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Tech tycoons, podcast bros and Hollywood stars are all piling money into full-body scans, which deploy AI in the hope of catching everything from high cholesterol to cancer. Is this the first step to ...

Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years- Company is eligible to receive a $40 million milestone payment upon first ...

Thyroid level tests, including thyroid-stimulating hormone (TSH) and free T4, help diagnose underactive or overactive thyroid. Doctors may also check free T3, calcitonin, thyroglobulin, or thyroid ...